Palladin isoforms 3 and 4 regulate cancer-associated fibroblast pro-tumor functions in pancreatic ductal adenocarcinoma
Abstract Pancreatic Ductal Adenocarcinoma (PDAC) has a five-year survival under 10%. Treatment is compromised due to a fibrotic-like stromal remodeling process, known as desmoplasia, which limits therapeutic perfusion, supports tumor progression, and establishes an immunosuppressive microenvironment...
Enregistré dans:
Auteurs principaux: | J. I. Alexander, D. B. Vendramini-Costa, R. Francescone, T. Luong, J. Franco-Barraza, N. Shah, J. C. Gardiner, E. Nicolas, K. S. Raghavan, E. Cukierman |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c9c1c853b004496db22d52f9db2c5523 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma
par: Xingyi Pan, et autres
Publié: (2021) -
Advances in Pancreatic Ductal Adenocarcinoma Treatment
par: Eric M. Anderson, et autres
Publié: (2021) -
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma
par: Iranzu González-Borja, et autres
Publié: (2021) -
Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
par: Ole Helm, et autres
Publié: (2014) -
Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
par: Alexander G. Raufi, et autres
Publié: (2021)